Reported Characteristics of Anaphylaxis Associated With Glatiramer Acetate: A Pharmacovigilance Analysis of the FDA and Canadian Databases Authors: Tailei Nie, Hongyu Liu, Chuanxu Cheng, Jian Li, Jiajing Lu Published: 2026 ABSTRACT ABSTRACTThe FDA has mandated a Boxed Warning for glatiramer acetate (GA) due to the risk of serious anaphylactic reaction. This study aimed to characterize the reported features of GA‐associated anaphylaxis. Data mining was performed using the Reporting Odds Ratio (ROR) in the FDA Adverse Event Reporting System (FAERS) database (Q1 2004–Q1 2025) and the Canadian Vigilance Adverse Reaction (CVAR) database (Q1 1996–Q1 2025). Demographic characteristics, time‐to‐onset (TTO), and case seriousness were compared using the Mann–Whitney U test or the Chi‐squared (χ 2) test. In the FAERS database, 9816 reports were identified with 29 significant disproportionality signals. Younger age (p < 0.01) was significantly associated with a higher proportion of serious reports. The association between GA and anaphylactic AEs remained statistically significant after stratification by age, body weight, sex, and reporter types. Twenty AEs demonstrated significantly higher reporting rates in serious cases (p < 0.05). Clinical prioritization identified 9 moderate‐priority and 20 weak‐priority signals. The median TTO was 197 days for moderate‐priority signals versus 153 days for weak‐priority signals. All signals exhibited early failure‐type patterns, indicating that reported anaphylactic events were more frequently observed earlier after treatment initiation than later in treatment. In the CVAR database, 711 reports were identified. A total of 17 PTs overlapped with FAERS, with respiratory arrest uniquely present in CVAR. Three PTs were rated as moderate priority in the CVAR database but weak priority in FAERS. This large‐scale pharmacovigilance analysis of the FDA and Canadian databases characterizes the safety signals derived from GA‐associated reports of anaphylaxis, providing a hypothesis‐generating foundation for future pharmacovigilance validation.Keywords: anaphylaxis, CVAR, FAERS, glatiramer acetate, pharmacovigilance Introduction GA, a synthetic polypeptide that mimics myelin basic protein, has been a first‐line disease‐modifying therapy for relapsing–remitting multiple sclerosis (MS) since its approval by the FDA in 1996 [1, 2]. Its mechanism of action, which involves inducing regulatory T‐cells to suppress neuroinflammation, offers favorable efficacy with historically fewer systemic risks than interferon‐based therapies or newer immunosuppressants [3]. However, post‐marketing surveillance has identified rare but potentially severe hypersensitivity reactions, leading the FDA to issue a 2025 Boxed Warning regarding the risk of anaphylaxis [4]. This regulatory step underscores significant gaps in understanding the real‐world safety profile of this drug. Anaphylaxis is a medical emergency characterized by rapid onset and multisystem hypersensitivity, affecting the respiratory system (bronchospasm, laryngeal edema), cardiovascular stability (hypotension, tachycardia), and skin (urticaria, angioedema) [5]. Mortality rates approach 1%, despite the availability of epinephrine, with delayed recognition being a major factor [6]. GA's molecular structure—consisting of glutamic acid, lysine, alanine, and tyrosine—may function as a hapten, binding to endogenous proteins to form neoantigens that induce IgE‐mediated mast cell degranulation [7]. Cross‐reactivity between GA epitopes and myelin autoantigens could further enhance immune activation in susceptible MS patients [8]. Paradoxically, although intended to modulate autoimmunity, this immunogenicity may also contribute to its potential for causing anaphylaxis. Current evidence on GA‐associated anaphylaxis remains alarmingly limited. Clinical trials, powered for efficacy rather than rare adverse AEs, reported hypersensitivity incidence at 0.5%–1.5%, but methodological constraints obscure real‐world epidemiology [9, 10]. Existing pharmacovigilance studies suffer from: Temporal limitations: Inadequate follow‐up duration to capture delayed reactions; Temporal limitations: Inadequate follow‐up duration to capture delayed reactions; Case misclassification: Broad MedDRA terms (e.g., “hypersensitivity”) diluting anaphylaxis‐specific signals; Case misclassification: Broad MedDRA terms (e.g., “hypersensitivity”) diluting anaphylaxis‐specific signals; Unstratified analyses: Failure to account for age, sex, or comorbidity effects on severity; Unstratified analyses: Failure to account for age, sex, or comorbidity effects on severity; Inadequate clinical contextualization: Isolated disproportionality metrics without prioritization of life‐threatening events. Inadequate clinical contextualization: Isolated disproportionality metrics without prioritization of life‐threatening events. Consequently, clinicians lack evidence‐based guidance on risk stratification, monitoring protocols, or intervention timelines. Pharmacovigilance databases like the FAERS and CVAR databases offer unprecedented power to detect rare AEs through disproportionality analysis [11]. The reporting odds ratio (ROR) quantifies signal strength by comparing target drug‐event reporting frequency against background incidence [12]. When coupled with temporal analytics (time‐to‐onset, Weibull distribution modeling) and multidimensional clinical prioritization (fatality rates, designated medical events), this approach transforms raw AE data into actionable risk intelligence. Yet no comprehensive study has applied this integrated framework to GA‐associated anaphylaxis—a critical gap given its Boxed Warning status. This study leverages data from the FAERS and CVAR databases to address four pivotal aims: Signal Detection: Identify and validate anaphylactic signals through ROR and 95% confidence intervals across 87 Preferred Terms (MedDRA v22.1), with stratification by age, sex, weight, and reporter type; Signal Detection: Identify and validate anaphylactic signals through ROR and 95% confidence intervals across 87 Preferred Terms (MedDRA v22.1), with stratification by age, sex, weight, and reporter type; Clinical Phenotyping: Characterize demographic predictors, seriousness drivers, and outcomes of GA‐associated reports; Clinical Phenotyping: Characterize demographic predictors, seriousness drivers, and outcomes of GA‐associated reports; Signal Prioritization: Implement a semiquantitative scoring matrix evaluating reporting rates, signal stability, fatality, and clinical relevance (DME/IME status) to classify 29 signals into moderate/weak priority tiers; Signal Prioritization: Implement a semiquantitative scoring matrix evaluating reporting rates, signal stability, fatality, and clinical relevance (DME/IME status) to classify 29 signals into moderate/weak priority tiers; Temporal Analytics: Characterize time‐to‐onset (TTO) patterns using Weibull shape parameters to identify temporal windows with higher reporting frequencies. Temporal Analytics: Characterize time‐to‐onset (TTO) patterns using Weibull shape parameters to identify temporal windows with higher reporting frequencies. By integrating disproportionality analytics, clinical prioritization, and temporal dynamics, this analysis provides the characterization of GA‐associated anaphylaxis reporting patterns, offering hypothesis‐generating insights that warrant further investigation to inform post‐marketing safety surveillance and future safety evaluation strategies. Materials and Methods Data Source and Collection The pharmacovigilance study of GA‐associated anaphylaxis using post‐marketing data from the FAERS database (Q1 2004–Q1 2025) and CVAR database (1996–2025). FAERS adheres to International Council for Harmonization (ICH) E2B safety reporting guidelines and codes adverse events using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. Duplicate reports were resolved by [13] (1) retaining the latest submission (FDA_DT) for identical CASEID entries; (2) selecting the highest PRIMARYID when CASEID and FDA_DT match. AEs attributed to GA were identified at both System Organ Class (SOC) and Preferred Term (PT) levels. Drugs were categorized by reported role: primary suspect (PS), secondary suspect (SS), concomitant (C), or interacting (I). Target drugs included GA generics (glatiramer) and trade names (Copaxone, Glatopa); only AEs where GA was designated as PS were analyzed. This study removed duplicate cases and conducted disproportionality analysis in accordance with FAERS methods. A flow diagram including the multi‐step process of data extraction, processing, and analysis was shown in Figure 1. The process of selecting GA associated anaphylactic AEs from the FAERS and CAVR databases. n, number of cases with suspected AEs associated with the target drug; ROR, reporting odds ratio. Statistical Analysis The ROR, a key algorithm in disproportionality analysis, was calculated based on a 2 × 2 contingency table (Table S1). We included only anaphylactic AEs with at least three reported cases and ROR > 1. Signal strength for GA‐associated reports of anaphylaxis in the FAERS database was assessed, with a positive signal defined as a lower limit of the ROR 95% confidence interval (CI) greater than one [14]. Further compared serious and non‐serious reports to evaluate the severity of the detected safety signals and identify potential risk factors, including gender, age, and weight. Categorical variables were analyzed using Pearson's chi‐square (χ 2) or Fisher's exact test, while continuous non‐normally distributed data (e.g., age, weight) were assessed using the Mann–Whitney U test. All analyses were conducted in R 4.4, with statistical significance set at p < 0.05. To investigate whether stratification factors influenced the association between GA and anaphylactic AEs, we performed subgroup analyses by gender (female, male), age (18–64, > 65 years), weight (< 80, 80–100, > 100 kg), and reporter type (healthcare professional, consumer). Signal Prioritization Methodology AEs emerging with a significant association in at least one disproportionality analysis were ranked based on a semiquantitative score assessing the criteria listed in Table S2. The criteria contain [15]: clinical relevance, reporting frequency, signal stability, and case fatality rate. Time‐To‐Onset Analysis Time‐to‐onset (TTO) was defined as the interval between the AEs onset date (EVENT_DT in DEMO file) and start date of GA use (START_DT in THER file) [16]. To ensure the accuracy of this calculation, reports with input errors (EVENT_DT earlier than START_DT), inaccurate date entries, and missing specific data were excluded. The medians, quartiles, and the Weibull shape parameter (WSP) test were used to evaluate the TTO in our study [17]. The TTO statistical analysis was conducted using the WSP test, which could determine the varying ratio of incidence of AEs. The shape of the Weibull distribution was described by two parameters: scale (α) and shape (β). To evaluate whether the reporting frequency of these AEs over time, we calculated the median TTO and WSP of signals with strong, moderate, or weak clinical priority after GA use. The selection of parameters and criteria for evaluation was described in previous studies. All WSP tests were performed by R 4.4. Adverse Event and Drug Identification According to Medical Dictionary for Regulatory Activities (MedDRA, version 22.1) at the Preferred Term level, anaphylactic symptoms were chosen from the REAC files. All the anaphylactic PTs were listed in Table S3. Results Descriptive Analysis During the study period, a total of 18 625 995 AE reports were retrieved from the FAERS database after deduplication, including 13 435 reports of GA‐associated anaphylaxis affecting 9816 patients. Females predominated (7945, 88.3%) over males (1498, 11.7%). Anaphylactic reports occurred primarily in middle‐aged patients (18–65 years, n = 5251, 91.2%). The proportions of body weight > 100, 50–100, and < 50 kg were 16.6%, 79.3%, and 4.1%. Serious outcomes of anaphylactic and overall reports were recorded in 4052 and 20 482. Additionally, 63.2% of anaphylaxis reports were submitted by healthcare professionals (n = 5349, 63.2%), compared with 36.8% submitted by consumers (n = 3119, 36.8%). Multiple sclerosis (n = 6375, 79.8%) was the most reported indication. The country with the most anaphylactic reports (n = 7555, 77.4%) was the USA. The characteristics of the two database cases are largely comparable. In the CVAR database, 1 125 272 records were analyzed, identifying 711 reports of GA‐associated anaphylaxis. Females comprised the majority of cases (302, 83.4%). Anaphylactic AEs occurred most frequently in the middle‐aged group (304, 95.6%). In terms of body weight, 86.4% of patients weighed between 50 and 100 kg, while 13.7% weighed over 100 kg. A total of 57 serious anaphylactic reactions and 191 serious overall AEs were reported. Healthcare professionals and consumers submitted a comparable number of anaphylaxis reports. The detailed characteristics were summarized in Table 1. TABLE 1Reported characteristics of patients with GA‐associated anaphylactic AEs from FAERS and CVAR databases.CharacteristicsFAERSCVARAnaphylactic AEsn = 9816Overall AEsn = 51 433Anaphylactic AEsn = 365Overall AEsn = 986Available numberAvailable numberAvailable numberAvailable number Gender, n (%) Female7945 (88.3%)39 272 (80.8%)302 (83.4%)782 (80.5%)Male1498 (11.7%)9331 (19.2%)60 (16.6%)189 (19.5%) Age (years), n (%) < 1875 (1.3%)325 (1.3%)3 (0.9%)10 (1.2%)≤ 18 and ≤ 655251 (91.2%)21 125 (87.3%)304 (95.6%)760 (94.8%)> 65432 (7.5%)2738 (11.3%)11 (3.5%)32 (4.0%) Weight (kg), n (%) < 5057 (4.1%)247 (5.3%)08 (10.7%)≤ 50 and ≤ 1001116 (79.3%)3716 (79.5%)19 (86.4%)62 (82.7%)> 100234 (16.6%)713 (15.2%)3 (13.7%)5 (6.6%) Reported countries, n (%) United States7555 (77.4%)41 576 (81.2%)——Non‐United States2208 (22.6%)9628 (18.8%)—— Indications, n (%) Multiple Sclerosis6375 (79.8%)31 953 (62.1%)—— Relapsing–remitting Multiple sclerosis 597 (6.1%)2038 (4.0%)——Others1021 (12.8%)9295 (21.5%)—— Outcomes, n (%) Non‐serious outcome5764 (58.7%)30 951 (60.2%)162 (74.0%)335 (63.7%)Serious outcome4052 (41.3%)20 482 (39.8%)57 (26.0%)191 (36.3%) Reporters, n (%) Health professional5349 (63.2%)16 955 (38.0%)67 (37.4%)257 (47.5%)Consumer3119 (36.8%)27 705 (62.0%)112 (63.6%)284 (52.5%) Reporting year, n (%) Before 200462 (17.0%)135 (14.0%)2004–2010598 (6.1%)2618 (5.1%)43 (11.8%)120 (12.5%)2011–20152369 (34.1%)12 048 (23.4%)66 (18.1%)236 (24.5%)2016–20205143 (52.4%)27 496 (53.4%)112 (30.7%)286 (29.7%)2021–20151706 (17.4%)9235 (18.0%)82 (22.4%)185 (19.2%)Abbreviations: AEs, adverse events; n, number of cases. Reported characteristics of patients with GA‐associated anaphylactic AEs from FAERS and CVAR databases. Relapsing–remitting Multiple sclerosis Abbreviations: AEs, adverse events; n, number of cases. Disproportionality Analysis A total of 29 different PTs of the anaphylactic reports associated with GA were reported in the FAERS database (Figure 2), with values of signals ranging from a ROR of 1.31 (95% CI: 1.24–1.39, pruritus) to 23.51 (95% CI: 22.15–24.96, injection site urticaria). The most frequent anaphylactic AEs were dyspnoea (n = 2741, ROR = 2.18), urticaria (n = 1598, ROR = 4.41), flushing (n = 1397, ROR = 6.08). Results of the disproportionality analysis of the anaphylactic reports associated with GA were presented in Figure 2. The report frequency of anaphylactic reaction (n = 15 755, ROR = 1.88) related to GA was significantly higher than that of non‐anaphylactic reaction (n = 123 771, ROR = 0.53, 95% CI: 0.52–0.54) in the overall database. Among 27 SOCs, the results of Tables S4 and S6 demonstrated that anaphylactic reaction treated with GA exhibited stronger activity than most of the SOCs in these two database. Reporting odds ratios (ROR) with 95% CI for all positive GA related anaphylactic AEs in the FAERS database. CI, confidence interval; ROR, reporting odds ratio. In the CAVR database, as shown in Figure 3, several adverse reactions exhibit strong safety signals, particularly those related to immediate‐type hypersensitivity. Notably, injection site urticaria shows the highest ROR (n = 12, ROR = 22.11), followed by throat tightness (n = 53, ROR = 16.14) and pharyngeal swelling (n = 21, ROR = 9.37). In contrast, non‐anaphylactic reaction (n = 3588, ROR = 0.40) shows a lower incidence relative to anaphylactic reaction (n = 855, ROR = 2.52). Reporting odds ratios (ROR) with 95% CI for all positive GA related anaphylactic AEs in the CAVR database. CI, confidence interval; ROR, reporting odds ratio. A total of 17 PTs were common to both datasets. The CAVR database includes a more restricted set of PTs, with the unique addition of respiratory arrest, which is absent from the FAERS database. Despite these variations, the overlapping terms reinforce the core safety signal of hypersensitivity reactions associated with GA. Serious Versus Non‐Serious Cases Significant differences emerged between serious and non‐serious anaphylactic reaction cases in patients receiving GA (Table 2). Serious cases occurred in younger patients (median age 48 years, IQR 37–58 vs. 51 years, IQR 39–58; p < 0.01), while sex (p = 0.97) and body weight (p = 0.84) showed no significant intergroup differences. Twenty AEs demonstrated significantly higher reporting rates in serious cases (p < 0.05), including dyspnoea (χ 2 = 73.76, p < 0.01), chest discomfort (χ 2 = 22.98, p < 0.01), erythema (χ 2 = 55.97, p < 0.05), swelling face (χ 2 = 88.61, p < 0.01). Conversely, six AEs were predominantly reported in non‐serious cases: flushing (χ 2 = 53.51, p < 0.01), urticaria (χ 2 = 346.09, p < 0.01). Notably, all reported shock events (n = 6) resulted in serious outcomes. TABLE 2Differences in clinical characteristics of serious and non‐serious reports.Serious casesNon‐serious casesStatistic p Gender Female3324 (41.8%)4621 (58.2%)0 b 0.97 a Male628 (41.9%)870 (58.1%)——Age, years (median, IQR)48 (37–58)49 (38–58)−2.73 d < 0.01 c Weight, kg (median, IQR)78.28 (62–90.8)74.84 (63.4–90.7)−0.21 d 0.84 c Types of AEs Dyspnoea1525 (55.64%)1216 (44.36%)73.76 b < 0.01 a Chest discomfort556 (55.54%)445 (44.46%)22.98 b < 0.01 a Erythema546 (51.85%)507 (48.15%)5.97 b < 0.05 a Flushing542 (38.8%)855 (61.2%)53.51 b < 0.01 a Urticaria417 (26.1%)1181 (73.9%)346.09 b < 0.01 a Pruritus389 (34.64%)734 (65.36%)88.07 b < 0.01 a Swelling face346 (68.92%)156 (31.08%)88.61 b < 0.01 a Anaphylactic reaction294 (71.01%)120 (28.99%)87.95 b < 0.01 a Throat tightness282 (63.51%)162 (36.49%)42.46 b < 0.01 a Injection site urticaria244 (21.14%)910 (78.86%)363.10 b < 0.01 a Anaphylactic shock241 (72.16%)93 (27.84%)77.66 b < 0.01 a Swelling177 (39.16%)275 (60.84%)14.76 b < 0.01 a Lip swelling169 (69.26%)75 (30.74%)43.31 b < 0.01 a Swollen tongue116 (68.64%)53 (31.36%)27.85 b < 0.01 a Pharyngeal edema101 (70.63%)42 (29.37%)28.26 b < 0.01 a Choking84 (96.55%)3 (3.45%)80.09 b < 0.01 a Eye swelling68 (59.13%)47 (40.87%)5.14 b < 0.05 a Circulatory collapse64 (88.89%)8 (11.11%)46.41 b < 0.01 a Pharyngeal swelling53 (77.94%)15 (22.06%)23.06 b < 0.01 a Cyanosis50 (68.49%)23 (31.51%)11.33 b < 0.01 a Choking sensation48 (88.89%)6 (11.11%)34.37 b < 0.01 a Face edema40 (70.18%)17 (29.82%)10.23 b < 0.01 a Mouth swelling24 (72.73%)9 (27.27%)7.03 b < 0.01 a Hyperventilation20 (74.07%)7 (25.93%)6.27 b < 0.05 a Lip edema19 (90.48%)2 (9.52%)13.43 b < 0.01 a Anaphylactoid reaction10 (58.82%)7 (41.18%)0.41 b 0.52 a Skin swelling8 (25.81%)23 (74.19%)5.36 b < 0.05 a Shock symptom6 (100%)0——Upper airway obstruction4 (80%)1 (20%)—0.20 e a Proportions were compared using the Pearson χ 2 test. b The χ 2 statistic of the Pearson chi‐square test. c Mann–Whitney U test. d The Z statistic of the Mann–Whitney U test. e Fisher's exact test. p‐value < 0.05 was considered statistically significant. Differences in clinical characteristics of serious and non‐serious reports. Proportions were compared using the Pearson χ 2 test. The χ 2 statistic of the Pearson chi‐square test. Mann–Whitney U test. The Z statistic of the Mann–Whitney U test. Fisher's exact test. p‐value < 0.05 was considered statistically significant. Subgroup Analysis We performed subgroup analyses stratified by sex, age, body weight, and reporter type to evaluate the robustness of GA‐anaphylaxis associations. As shown in Figure 4, all stratified subgroups demonstrated consistent disproportionality signals, with RORs remaining statistically significant (lower bounds > 1). These findings confirm a persistent association between glatiramer acetate and anaphylactic reactions across demographic and reporting subgroups. Stratification analysis of GA related anaphylactic AEs in the FAERS database. CI, confidence interval; N, number of cases of total AEs associated with the target drug; n, number of cases with suspected AEs associated with the target drug; n1, number of cases of other drugs; ROR, reporting odds ratio. Clinical Prioritization of Disproportionality Signals Among 29 significant disproportionality signals (Table 3), 3 (10.3%) represented Important Medical Events (IMEs), while anaphylactic reaction, anaphylactic shock, and anaphylactoid reaction qualified as Designated Medical Events (DMEs). Clinical priority assessment categorized signals as Moderate priority (9 AEs, 31%) and Weak priority (20 AEs, 69%). Anaphylactic reaction and anaphylactic shock were assigned moderate priority, with the highest observed score of 4 (scoring criteria detailed in Table S2). The PTs marked with an asterisk, such as erythema (n = 1053) and chest discomfort (n = 1001), are rated as moderate priority in the CAVR database but weak priority in the FAERS database, despite having a relatively high number of reports in FAERS. Clinical priority assessment of results for disproportionality signals in the CAVR database is shown in Table S5. TABLE 3Clinical priority assessing results of disproportionality signals.PTs n RORDeath (n)DMEs/IMEsPriority level (score)Injection site urticaria115423.730NAWeak (2)Shock symptom68.440IMEModerate (3)Throat tightness a 4447.470NAWeak (2)Anaphylactic shock33463DMEModerate (4)Flushing13975.990NAModerate (3)Chest discomfort a 10014.462NAWeak (2)Urticaria15984.431NAModerate (3)Choking sensation544.390NAWeak (2)Pharyngeal edema1433.780NAWeak (2)Anaphylactic reaction4143.471DMEModerate (4)Pharyngeal swelling683.470NAWeak (2)Swelling face5023.460NAWeak (2)Lip swelling2443.260NAWeak (2)Mouth swelling332.610NAWeak (2)Upper airway obstruction52.460IMEModerate (3)Swollen tongue1692.380NAWeak (2)Erythema a 10532.220NAWeak (2)Lip edema212.180NAWeak (2)Dyspnoea27412.177NAModerate (3)Choking872.031IMEModerate (3)Hyperventilation272.030NAWeak (2)Cyanosis731.980NAWeak (1)Skin swelling311.870NAWeak (1)Anaphylactoid reaction171.820DMEModerate (3)Swelling4521.80NAWeak (1)Circulatory collapse721.771IMEWeak (2)Face edema571.470NAWeak (1)Eye swelling1151.40NAWeak (1)Pruritus11231.320NAWeak (1) Note: A score of 0–2, 3–5, and 6–8 was identified, respectively, for AEs with weak, moderate, or strong priority.Abbreviations: DME, designated medical event; IME, important medical event; PTs, preferred terms; ROR, reporting odds ratio. a Moderate priority in the CAVR database. Clinical priority assessing results of disproportionality signals. Note: A score of 0–2, 3–5, and 6–8 was identified, respectively, for AEs with weak, moderate, or strong priority. Abbreviations: DME, designated medical event; IME, important medical event; PTs, preferred terms; ROR, reporting odds ratio. Moderate priority in the CAVR database. Time‐To‐Onset Analysis TTO and WSP analyses for the moderate and weak clinical priority signals are shown in Table 4. The median TTO was significantly longer for moderate‐priority signals (197 days, IQR 54–643) than for weak‐priority signals (153 days, IQR 35–592). WPS analysis revealed shape parameters (β) < 1 for both signal categories: moderate priority (β = 0.63, 95% CI 0.61–0.66), weak priority (β = 0.58, 95% CI 0.56–0.6). Upper 95% confidence limits remained < 1, confirming early failure‐type distributions for both signal categories. This indicates that reported anaphylactic events were more frequently observed earlier after treatment initiation than later in treatment. TABLE 4Time‐to‐onset analysis for signals with moderate/weak prioritization.PrioritizationWeibull distributionCaseTTO (days)Scale parameterShape parameter n Median (IQR)Min‐max α 95% CI β 95% CIModerate1644197 (54–643)1–7316399.53367.36–431.70.630.61–0.66Weak1824153 (35–591.25)1–7502335.41307.55–363.270.580.56–0.6 Note: When TTO is 1 day, the adverse event occurred on the same day as the therapy.Abbreviations: IQR, interquartile range; n, number of cases with available time‐to‐onset; TTO, Time‐to‐onset. Time‐to‐onset analysis for signals with moderate/weak prioritization. Note: When TTO is 1 day, the adverse event occurred on the same day as the therapy. Abbreviations: IQR, interquartile range; n, number of cases with available time‐to‐onset; TTO, Time‐to‐onset. Discussion This pharmacovigilance study leverages FAERS and CVAR data to characterize GA‐associated anaphylactic reports, addressing critical gaps highlighted by the FDA's 2025 Boxed Warning. Although many studies were consistent with previous clinical trials and literature reviews that GA might increase the risk of anaphylactic reactions, our report presents a more accurate and detailed description and characterization of the anaphylactic AEs spectrum of GA to date, which added stratification analysis, clinical priority of signals, and serious outcomes. Comparison of Safety Signals Between Different Studies This study provides a large‐scale pharmacovigilance analysis of GA‐associated reports of anaphylaxis using data from the FAERS and CVAR databases, which complements findings from earlier clinical trials and smaller‐scale studies by real‐world reporting patterns. The current study showed that the most frequently reported anaphylactic AEs were dyspnoea (n = 2741, ROR = 2.18), urticaria (n = 1598, ROR = 4.41), and flushing (n = 1397, ROR = 6.08), which corresponded to clinical trials [18]. The unique PT respiratory arrest identified in the CVAR database constitutes a safety signal suggesting that glatiramer acetate may be associated with a rare but potentially life‐threatening respiratory event. Previous research and clinical trials have reported GA's hypersensitivity incidence at 0.5%–1.5%, with more limited case details provided in safety surveillance data [19, 20]. Our analysis features in‐depth disproportionality analysis and stratification across multiple demographic and reporting variables. The signals identified in this study, including those for dyspnoea (n = 2741, ROR = 2.18), urticaria (n = 1598, ROR = 4.41), and anaphylactic reactions (n = 17, ROR = 1.81), align with previous findings regarding common allergic reactions [21], but the detailed characterization, especially the time‐to‐onset (TTO) analysis, provides new insights. Specifically, the time to onset of anaphylactic reactions ranged significantly between moderate and weak‐priority signals, suggesting that while some reactions occurred earlier (within 153 days), others manifested after a longer delay (up to 197 days). Our research is similar to the FDA's box warning [4]: allergic reactions to this medication may occur up to 6 months after administration. These findings may warrant further investigation regarding the timing of reported allergic reactions and their potential implications for patient monitoring. This study suggests that while the hypersensitivity risk is well‐recognized, the heterogeneity of reactions and the variability in timing observed in spontaneous reports highlight distinct safety signals. Moreover, unlike the broader category of hypersensitivity in prior studies [22, 23, 24], our research provides a detailed characterization of specific anaphylactic symptoms and their relative reporting associations. These hypothesis‐generating findings warrant further investigation to inform potential patient safety monitoring considerations. Serious Versus Non‐Serious Reports A notable finding from our analysis is the difference between serious and non‐serious outcomes among GA‐associated reports of anaphylaxis. Our results showed that while most adverse events were not serious, serious AEs such as dyspnea, anaphylactic shock, and chest discomfort made up a significant part of the reports. Previous studies have rarely addressed these severe AEs [24], and this study fills that gap. Younger age was associated with the reporting of serious versus non‐serious reactions, with serious reports having a lower median age (48 vs. 51 years, p < 0.01). Previous studies did not mention differences in the occurrence of adverse reactions based on gender or age [25]. On the other hand, the non‐serious reactions, including urticaria and pruritus, were more frequently reported, which aligns with the general understanding that milder forms of hypersensitivity are more common but less clinically significant [21, 24]. Importantly, our study demonstrated that specific events, such as anaphylactic shock, were strongly associated with serious outcomes, which may warrant further investigation regarding their potential implications for patient monitoring. These findings suggest that while many reactions are mild and self‐limited, signals of severe hypersensitivity, particularly in younger age groups and during the early phase of treatment, merit further investigation. Given the risk of life‐threatening reactions like anaphylactic shock, future studies should evaluate whether specific symptom patterns are associated with more serious reported outcomes. Clinical Prioritization of the Disproportionality Signals The clinical prioritization of safety signals is an essential component of pharmacovigilance, as it allows for the identification of adverse events that require immediate attention. In this study, we classified 29 signals associated with GA‐associated reports of anaphylaxis into moderate and weak clinical priority categories in the FAERS database. Notably, anaphylactic shock and anaphylactic reaction were classified as moderate‐priority signals, given their potential to cause severe, life‐threatening outcomes [26]. Erythema (n = 1053) and chest discomfort (n = 1001) are rated as moderate priority in the CAVR database but weak priority in the FAERS database, despite having a relatively high number of reports in FAERS. The differential prioritization of PTs, such as throat tightness and chest discomfort, between CAVR and FAERS illustrates the complementary nature of these databases. While FAERS provides a broad‐based safety overview, CAVR contributes regional depth, making it an essential tool for identifying and contextualizing drug safety signals. This prioritization is consistent with previous studies that emphasize the importance of early detection and rapid intervention in cases of anaphylactic shock [27]. The moderate‐priority classification for signals like dyspnoea and throat tightness underscores the need for clinical vigilance in patients presenting with respiratory distress, as these symptoms can escalate into more severe forms of anaphylaxis [28]. By contrast, the weak‐priority signals, including urticaria and pruritus, were deemed less urgent but still important for monitoring, given their relatively high frequency in the reports [24]. Limitations Despite the advantages of real‐world data mining strategies utilized in our study based on the FAERS and CVAR databases, there were several limitations inherent in all pharmacovigilance databases. First, only cases with adverse events are included in the databases. The incidence of anaphylactic reports associated with GA cannot be calculated because the total number of patients receiving GA treatment is unknown. Second, the establishment of a definite causal relationship between a target drug and AEs is restricted because disproportionality analysis only provides statistical association. Third, we focus only on AEs in one reaction group, and the deep relationship between GA and other system organ classes remains unknown. Further experimental exploration, clinical trials, case–control studies, and cohort studies are needed to validate the results. Conclusion This pharmacovigilance study presents a comprehensive real‐world analysis of GA‐associated anaphylactic reports, identifying 29 clinically relevant signals, including 9 moderate and 20 weak‐priority events. Key findings reveal that younger age (p < 0.01) was associated with a higher proportion of serious anaphylactic AEs, whereas body weight and sex showed no significant correlation with severity. Temporal analysis demonstrated a median TTO of 197 days for moderate‐priority signals and 153 days for weak‐priority signals, with all signals exhibiting early failure‐type patterns, suggesting that reported events occurred more frequently within the first 6 months after treatment initiation. These findings expand the post‐marketing safety knowledge of GA and underscore the need for independent validation through well‐designed pharmacoepidemiologic studies. Author Contributions Tailei Nie: writing – original draft, writing – review and editing, methodology. Jiajing Lu: conceptualization, investigation, funding acquisition, writing – original draft, writing – review and editing, visualization, validation, methodology, software, formal analysis, project administration, resources, supervision, data curation. Hongyu Liu: validation, formal analysis, visualization. Jian Li: software, data curation, visualization. Chuanxu Cheng: software, data curation, visualization. Funding This work was supported by the Young Scientists Fund of the National Natural Science Foundation of China (Grant No. 82404600). Ethics Statement Since this study used publicly accessible anonymized data from the database, institutional ethical approval was not necessary. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Table S1: Calculation of reporting odds ratio (ROR). Table S2: Criteria and relevant scores to prioritize AEs emerged from disproportionality analysis. Table S3: Anaphylactic PTs from MedDRA, version 22.1. Table S4: Signal strength of reports of glatiramer at the System Organ Class (SOC) level in the FAERS database. Table S5: Clinical priority assessment of results for disproportionality signals in the CAVR database. Table S6: Signal strength of reports of glatiramer at the System Organ Class (SOC) level in the CAVR database.